UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or ...

OncoCyte Corporation (NASDAQ:OCX) Q2 2019 Results Earnings Conference Call August 14, 2019 4:30 PM ET Company Participants Glenn Garmont - IR, LifeSci Advisors Ronald Andrews - CEO, President Al Parker - Chief Operating Officer Mitchell Levine - CFO Tony Kalajian - Chief Accounting Officer Lyndal Hesterberg - Chief Scientific Officer Conference Call Participants Paul Knight - Janney Montgomery Scott Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The Benchmark Company Keay Nakae - Chardan Capita ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ (I.R.S. Employer Identification No.) 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 (Address of principal executive offices) (Zip Cod ...

OncoCyte Corporation (NASDAQ:OCX) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Bob Yedid - IR, LifeSci Advisors William Annett - President and CEO Mitch Levine - CFO Lyndal Hesterberg - SVP, Research & Development Conference Call Participants Bill Quirk - Piper Jaffray Bruce Jackson - The Benchmark Company Casey Woodring - Janney Montgomery Scott Operator Good day and welcome to the OncoCyte Conference Call to discuss First Quarter 2019 Financial Results and Operating Highl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or other ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2018 Results Earnings Conference Call April 1, 2019 4:30 AM ET Company Participants Bob Yedid - Investor Relations, Managing Director at LifeSci Advisors William Annett - President, Chief Executive Officer Mitch Levine - Chief Financial Officer Lyndal Hesterberg - Senior Vice President of Research & Development Conference Call Participants Bill Quirk - Piper Jaffray Paul Knight - Janney Montgomery Scott Bruce Jackson - The Benchmark Company Keay Nakae - Chardan Capital M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

OncoCyte Corporation (NASDAQ:OCX) Results from Key R&D Validation Study January 29, 2019 8:30 AM ET Company Participants Bob Yedid – Managing Director-LifeSci Advisors Bill Annett – President and Chief Executive Officer Lyndal Hesterberg – Senior Vice President-Research and Development Al Parker – Chief Operating Officer Ronnie Andrews – Board of Director-Science and Technology Committee Conference Call Participants Paul Knight – Janney Montgomery Scott Caroline Palomeque – Maxim Group Kevin DeGeeter – Oppe ...